I listened to the call two times and there was a caller that specifically asked "how confident are you with being able to move into Ph2 registration trial for 907". Ali mentoined that based on data availablbe as of that moment they are confident of a ph2 during 2nd half. A lot depends on the benefit 907 does to cancer patients under trial. hoping for the best.
I guess whatever information was imparted to investors during the one-on-one meeting at the Deutsche conference did not scare them off. Perhaps the conference also explains why so few analysts attended the telephonic earnings conference call. All eyes are looking to the press release sure to come on the morning of May 14th or even the evening of May 13th after the 5:00 p.m. release of the abstract.
ASCO unlike what I expected will include latest data of the expansion phase and any available combo theraphy results too. I think it is exciting phase for curis. longs what you think? any longs other than bent still hanging on still??
during this call. safety consistent with what is expected. also to be noted that aurigene collaboration molecules are competing in area dominated by biologics so will be cheaper alternatives. overall I felt it is a potential $5 company in the short run on good results from cudc907 from expanded phase. Further future remains speculative but significant.
and what more did you expect during this release? obviously they were to report loss due to expense with the aurigene collaboration, they have 907 with orphan drug desig, planning for registration directed Ph2 trial later this year with 907, aurigene is moving ahead with the phl1/2 immuno-oncology platform. Pretty sure nobody was expected to get results from the extended ph1 trial now. Overall the release was good give the stage (so long as they are not lying).
the abstract in December 2013 at ASH caused the stock to drop appreciably due to lackluster preliminary findings regarding 907's efficacy; let's hope the release of the abstract at ASCO has the opposite effect. At earnings conference, CEO raised possibility of 907 being tested in combination with another drug, (did not catch its name). I assume that would be for the treatment of myeloma. Pretty vague regarding when data would be reported on solid tumors.
It was very vanilla. Not bad, not good....now we wait for abstract publication on the 13th.....and the rest of the calendar year........
i road it up then. sold and paid off good chunk of mortgage. then bought some back a little lower and ... road it down. learned a lot since then. but, what am i doing here now?
I think he should have said "potentially transformative decade." I will be dead and gone but hopefully my children will benefit if, in fact, Curis, does transform itself into a full fledged pharmaceutical company as it promised in its prospectus when the stock shot up from $2 to $28 in a span of three months in late 1999, early 2000.
A Lexington, Mass biotech was bought out today. Maybe some day we long term shaeholders will get rewarded as well.
Synageva BioPharma Corp. - NASDAQ
203.39 107.52 (112.15%)
As of 4:00 PM EDT - U.S Markets Closed
Roche (Genetech) disclosed this a year ago indicating that phase 1 study showed that using Erivedge in conjunction with operable BCC was not efficacious. News further contributed to decline in price of stock at that time as it became clear Erivedge would have little application beyond treatment of those patients with inoperable BCC. This article should have no impact on the current price of the stock as all eyes are on Curis' own drugs and those coming out of its collaboration with Auriegene.